The mean dithiothreitol (DTT)-activated activity of erythrocytIc -aminolevulinate dehydratase (ALAD,EC 4.2.1.24, porphobilinogen synthase) in 20 nondiabetic subjects was 30.5 (SD 4.0) U per liter of erythrocytes; in 79 diabetics, this activity was 19.4 (SD 6.3) U/L, significantlyless(P <0.001). Further This zinc-containing enzyme, Mr 250 000, is composed of eight subunits, each of Mr about 35 000 (1) The enzyme requires sulthydryl groups for its activity. These may not be part of the active site, but they do participate in the activation of the apoenzyme by Zn2 and (or) in the formation and stabilization of the active dimers, tetramers, or octamers (1). Oxidation of the SH groups or their inactivation-.e.g., by lead-leads to loss of activity, which can be completely restored in vitro by adding dithiothreitol (DTT) (2). D'Vl' increases the activity of erythrocyte
was 19.4 (SD 6.3) U/L, significantlyless(P <0.001). Further, we observed a significant (P <0.01) negative correlation between activated ALAD activity and the concentration of giycated hemoglobin in the diabetics (r = -0.58).Hemolysate incubated in a 75 mmol/L solution of glucose in isotonic saline for 48 h at 37 #{176}C lost more activated ALAD activity than did hemolysate incubated in 75 mmol/L glycerol in isotonic saline. Enzyme kinetic studies showed this loss of activity to be noncompetitive. Our data suggest that the loss of erythrocytic ALAD activity in diabetics, paralleling the increase in glycated hemoglobin concentrations, probably results from glycation of this enzyme.
&.Aminolevulinate dehydratase (A.lAn; EC 4.2.1.24; porphobilinogen synthase; 5-aminolevulinate hydrolyase) catalyzes the formation of a pyrrole ring from two molecules of aminolevulinic acid (ALA),' the second step in the biosynthesis of porphyrin.
This zinc-containing enzyme, Mr 250 000, is composed of eight subunits, each of Mr about 35 000 (1) The enzyme requires sulthydryl groups for its activity. These may not be part of the active site, but they do participate in the activation of the apoenzyme by Zn2 and (or) in the formation and stabilization of the active dimers, tetramers, or octamers (1) . Oxidation of the SH groups or their inactivation-.e.g., by lead-leads to loss of activity, which can be completely restored in vitro by adding dithiothreitol (DTT) (2) . D'Vl' increases the activity of erythrocyte
ALAn in
healthy persons, suggesting that some of the enzyme is in an oxidized state in erythrocytes. The mechanism of the enzyme action (1) involves the formation of a Schiff base between the e-NH group of a specific lysine residue of MAD and the carboxyl group of ALA.
A report describing low activities of ALAD in diabetic rat livers (3) led us to assay this enzyme in the erythrocytes of human diabetics. We examined the activationofthe enzyme by DTT and assessed the severityofthe diabetes by measuring glucose and glycated hemoglobin in the blood.
Materials and Methods

Subjects:
We studied routine hepannized blood specimens sent to the laboratory from 34 men and 45 women (ages 17 to 77 y) with diabetes mellitus.
We were able to obtain Department ofBiochemistry, Royal Melbourne Hospital, Grattan St., Parkville, Victoria 3050,Australia.
clinical information on 69 patients only. Of these, 26 were Type I (insulin-dependent) diabetics, 42 were Type II (noninsulin-dependent) diabetics, and one had diabetes secondary to a pancreatectomy. The Type I diabetics had had the disease for an average of 21 years (range: 2 to 50 y) and the Type II diabetics for an average of 11 years (range: 0.5 to 33 y). All patients were on treatment for their diabetes. The control group consisted of 20 apparently healthy laboratory workers, 10 men and 10 women (ages 22 to 43 y).
Samples were divided into aliquots and stored at -70 'C until assay of A.1.n and glycated hemoglobin. We also had received samples in fluoride-heparin tubes for glucose anal- Glycated hemoglobin: We assayed glycated hemoglobin in hemolyzed whole blood by using the "Glytrac" system (Corning Medical, Palo Alto, CA) at pH 6.3. The reagents include a buffer containing 1 g of saponin, 500 mg of EDTA, and 50 mmol of potassium biphthalate per liter (pH 5.0) to remove labile hemoglobin. The gels were subsequently scanned in a Corning fluorodensitometer at 420 nm.
Glucose: We determined the concentrations of glucose in plasma with an "Astra-8" analyzer (Beckman Instruments Inc., Brea, CA) and Beckman reagents. Whole-blood hemolysates were assayed in an "AutoAnalyzer II" (Technicon Instruments Corp., Tan-ytown, NY) with a glucose oxidase method modified from the method of Morley et al. (4) .
ALAD: ALA!) was measured by a modification of the method of Berlinand Schaller(5). Stored samples were thawed at room temperature.
We incubated 50 L of whole-blood hemolysate at 37 #{176}C for 60 mm in MES buffer (42 mmol/L, pH 6.8) containing 10 g of saponin and 8.3 mmol of ALA per liter. To assay activated ALAD, we added to the incubation mixture 32 mmol of DII' per liter. Enzyme activity was calculated as micromoles of porphobilinogen formed per minute per liter of erythrocytes (UIL). The between-run CV of the assay for AiA at 15 UJL was 6.4%; for activated ALAD at 21 UIL it was 7.2%. Hematocnts were determined with a Coulter Counter (CoulterElectronic Inc., Hialeah, FL).
In vitro glycation arperiment: We collected 20 mL of blood from a healthy laboratory worker into two tubes containing lithium heparin as anticoagulant.
After centrifuging these (3000 x g, 10 mm), we replaced each plasma supernate with an equivalent volume of isotonic saline (control) or glucose- the hemolysate. However, incubation of the hemolysates for 48 h at 37 #{176}C in the presence of glucose-saline showed there was significant (P <0.01) loss of ALAD activity compared with that of the control hemolysate in saline or glycerolsaline-a loss not reversible by D'l'T or by Zn2 (Figure 3) . The results of the experiments in which glycerol-saline was used as control are shown in Figure 4 . The Lineweaver-Burk plot ( Figure 5 ) shows that the maximal velocity of the activated ALAD reaction in the hemolysate incubated in glucose-saline 28.6 (SD 3) U/L is significantly (P <0.01) lower than that of the enzyme in the hemolyste incubated in saline 41.7 (SD 7) UIL. However, the 
and thawing at room temperature. At time zero, some aliquots of the hemolysate were frozen at -70 'C, the rest being placed in an incubator set at 37 #{176}C. Further aliquots were removed from the incubator at 12, 24,36, and 48 h, and stored at -70 #{176}C until assayed. To control for possible loss of activity due to an osmotic effect of the high concentration of glucose used, the experiments were repeated with the control hemolysate incubated in an glycerol-saline solution that was osmotically equivalent to the glucose-saline solution used for the test.
The assays for activated ALAD were performed as described above and also with the addition of 1 mmol of Zn2 per liter to the final reaction mixture, because an adequate concentration of Zn2 + has been described as essential for this enzyme's activity (1, 6). Glycated hemoglobin was also measured in the samples over the same period of incubation (see Figure 4 
below).
Determination of the Km: Michaelis constants for the ALA!) in the hemolysates obtained at the end of the glycation experiment were determined in the presence of DII' and Zn2, with substrate concentrations ranging from 0.16 to 10 mmol of ALA per liter.
Statistical
analysis:
We used Student's t-test to assess statistical significance. The significance of the correlations (using standard linear regression method) between activated ALAD activity, whole-blood glycated hemoglobin concentration, and plasma glucose concentrations were calculated according to Heel (7).
Results
MAD and ALA!) in diabetics. Table 1 shows that the activity of ALA!) is significantly lower in diabetics than in control subjects, and that the activity is not fully restored by DII'.
Activated ALA!) and severity of diabetes. Figure 1 shows that there is a significant negative relationship (P <0.01) between severity of the diabetic state, as reflected by the glycated hemoglobin levels, and the activated AL.AD levels (r = -0.58, n = 79). This negative relationship was present in both Type I diabetics (r = -0.44, n = 26, P <0.05) and Type H diabetics (r = -0.69, n = 42, P <0.01).
There was also a close negative relationship (P <0.01) between current blood glucose concentration and concentration of activated ALA!) (r = -0.40, n = 54), as shown in Figure 2 . We also found a significant (P <0.01) positive relationship between current glucose values and glycated hemoglobin (r = 0.50, n = 54).
There was no significant relationship between activated ALA!) activity and the duration of diabetes in either Type I or Type II diabetics.
Mode of inhibition
by glucose. Glucose does not directly inhibit the enzyme, even at a concentration of 75 mmolIL in 
Discussion
We show here that diabetic patients have significantly lower ALA!) and activated Ai.t) activities than do normal persons. We have also shown a significant negative correlation between glycated hemoglobin and activated-AL...kn activ-.2 2, . e .c. ity in both Type I and Type II diabetics. The loss of activated-ALAD activity in diabetic patients may be due to decreased synthesis of the enzyme protein, direct inhibition by glucose or other inhibitors, or inhibition of enzyme activity by glycation of the enzyme.
Decreased synthesis of erythrocyte ALA!) in diabetics is a possibility that we have not investigated, but we think it unlikely in view of our in vitro incubation experiments with glucose which led to loss of enzyme activity. It would also be unlikely that such a decrease in enzyme synthesis would bear a close relationship to glycated hemoglobin concentration.
The loss of activity is not due to oxidation or deactivation of sulthydryl groups as caused by the commonest described inhibitors of ALA!) such as lead, because the loss of activity is not reversed by DTT. In diabetic patients the enzyme is activated by DII' (average 152%) to a similar extent to that of normal persons (average 134%), so that the final activated ALA!) activity is significantly lower (See Table 1 ). This is in marked contrast to inactivation of the enzyme by lead, where activation of the order of five-to 10-fold by DII' restores activated-ALA!) values to normal (2) .
Direct inhibition by glucose is a possible explanation, because there was a significant correlation between current patient glucose levels and activated ALAD activity in their erythrocytes ( Figure 2 ). But direct inhibition by glucose seems unlikely, because addition of 75 mmol of glucose per liter did not inhibit enzyme activity, as is seen by the zerotime assays in our in vitro glycation experiment (Figure 3) . The relationship between current glucose concentrations in the patient's plasma and activated-AIAD activity is similar to the relationship observed between current glucose concentrations and glycated hemoglobin concentrations.
The loss of activated ALA!) activity during a 48-h incubation at 37 'C in glucose-saline shows a slow inactivation of the enzyme (Figure 3) . Further, this loss of activity is seen in the presence of DTT and Zn2 , which would have reversed any SH-group oxidation or loss of activity due to lack of Zn2 (6). The Lineweaver-Burk plots ( Figure 5) show the loss of activity to be noncompetitive, because the maximum reactionvelocitywas significantly decreased but the Km remained unchanged. Such kinetics would be seen if some of the enzyme was totally inactivated during the incubation. We suggest that this slow inactivation is due to glycation of the enzyme.
Glycation of a protein occurs via Schiff base formation at free-NH2 sites such as the terminal valine-NH2 group of the B chain of hemoglobin. This initial "labile" bond is stabilized by an "Amadori" rearrangement (8) . NH2 groups of lysine residues within the molecule could be glycated, and this could occur at more than one site (9) . The effect on enzyme activity would depend on which residues were involved. Agai-wal et al. (10) described the in vivo glycation of erythrocyte purine nucleoside phosphorylase with no change in activity. Activity could be lost if the active site or sites were among the NH2 groups glycated. This would alter the conformation of the active site. In vitro glycation of bovine ribonuclease A with loss of activity has been described (11) .
The activity of ALAD is dependent on Schiff base formation between the substrate ALA and the #{128}-amino group of a specific lysine residue of the enzyme (1) . If this lysine residue were to be glycated by Schiff base formation with glucose it would lead to loss of enzyme activity, a loss not reversibleby added DTT or Zn2 . The extent of glycation as in the case of glycated hemoglobin would depend on the concentrationof glucose surrounding the erythrocyte during its life span. Hence the concentration of activated ALAD would vary with the degree of diabetic control as does the concentration of glycated hemoglobin.
